Hepion Pharmaceuticals (HEPA) Stock Price, News & Analysis

Company Overview

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Key Stats

• Today's Range: $0.59 to $0.64
• 50-Day Range: $0.57 to $0.82
• 52-Week Range: $0.55 to $4.47
• Volume: 25,204 shs
• Average Volume: 85,344 shs
• Market Capitalization: $4.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Hepion Pharmaceuticals Stock Analysis - MarketRank™

Hepion Pharmaceuticals scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Hepion Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Hepion Pharmaceuticals is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hepion Pharmaceuticals is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Hepion Pharmaceuticals has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.13% of the float of Hepion Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Hepion Pharmaceuticals has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hepion Pharmaceuticals has recently increased by 247.62%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hepion Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Hepion Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.13% of the float of Hepion Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Hepion Pharmaceuticals has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hepion Pharmaceuticals has recently increased by 247.62%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.22

News Sentiment

Hepion Pharmaceuticals has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Hepion Pharmaceuticals this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for HEPA on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Hepion Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.95% of the stock of Hepion Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 17.24% of the stock of Hepion Pharmaceuticals is held by institutions.

HEPA Stock Analysis - Frequently Asked Questions

How have HEPA shares performed this year?

Hepion Pharmaceuticals' stock was trading at $3.24 at the beginning of the year. Since then, HEPA shares have decreased by 80.9% and is now trading at $0.62.
View the best growth stocks for 2024 here.

How were Hepion Pharmaceuticals' earnings last quarter?

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) issued its quarterly earnings results on Sunday, November, 15th. The company reported ($13.80) earnings per share for the quarter, missing analysts' consensus estimates of ($10.20) by $3.60.

When did Hepion Pharmaceuticals' stock split?

Hepion Pharmaceuticals's stock reverse split on Thursday, May 11th 2023. The 1-20 reverse split was announced on Thursday, May 11th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Hepion Pharmaceuticals' major shareholders?

Hepion Pharmaceuticals' top institutional investors include Anson Funds Management LP (3.33%). Insiders that own company stock include Robert T Foster and Peter Wijngaard.
View institutional ownership trends.

How do I buy shares of Hepion Pharmaceuticals?

Shares of HEPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Hepion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Hepion Pharmaceuticals investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), FuelCell Energy (FCEL), NVIDIA (NVDA), Tonix Pharmaceuticals (TNXP), Advanced Micro Devices (AMD) and Meta Platforms (META).

Company Calendar

• Last Earnings: 11/15/2020
• Today: 11/18/2024
• Next Earnings (Estimated): 11/18/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HEPA
• CUSIP: N/A
• CIK: 1583771
• Web: www.hepionpharma.com
• Phone: (732) 902-4000
• Fax: 732-902-4100
• Employees: 20
• Year Founded: 2013

Profitability

• EPS (Most Recent Fiscal Year): ($4.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-48,930,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -512.95%
• Return on Assets: -169.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.62
• Quick Ratio: 5.62

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.29 per share
• Price / Book: 0.48

Miscellaneous

• Outstanding Shares: 6,960,000
• Free Float: 6,822,000
• Market Cap: $4.32 million
• Optionable: No Data
• Beta: 1.81